Drug Database
Back to search

Belgium· BE-AMP-SAM458231-00

Adempas 2 mg

A riociguat product containing riociguat, registered in Belgium by Bayer. The same ATC class is registered in 17 of our 19 countries.

ATC C02KX05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAdempas 2 mgATCC02KX05REGISTER NO.BE-AMP-SAM458231-00PACKS LISTED4CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about riociguatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Riociguat is registered in 17 of 19 countries.

Countries holding a registration under ATC C02KX05 (riociguat), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose
Search riociguat products by name

Riociguat · ATC C02KX05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of riociguat costs, country by country.

Normalised to the WHO defined daily dose (4.5 mg), the median price runs from $0.056 in France to $219.06 in Switzerland — a ×3926 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Riociguat · price per daily dose (4.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$219.06
  • IT Italy$147.94
  • FR France$0.056
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Riociguat
Manufacturer
Bayer
Country
Belgium (BE)
ATC code
C02KX05
ATC class
Riociguat
Defined daily dose
4.5 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 4

  • be_apb
    3144128
  • be_apb
    7708639
  • be_apb
    3144110
  • be_apb
    7738305

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

140 interactions on record for riociguat.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check riociguat against other medicinesHow interaction checks work

Riociguat · interactions on record

140 records

  • 10 severe
  • 103 moderate

Most severe, free to view

  • DipyridamoleB01AC07severe
  • DipyridamolC01DX29severe
  • TheophyllinC01EB28severe
  • KetoconazoleH02CA03severe

27 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Riociguat in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All riociguat products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Austria · Pahrilan
  • Cyprus · Ridecia
  • Finland · Midive, Riociguat
  • Greece · Ridecia, Riociguat Win Medica
  • Iceland · Adempas
  • Liechtenstein · Adempas
  • Malta · Midive, Riociguat
  • Netherlands · Pahrilan
  • Norway · Adempas
  • Sweden · Pahrilan, Ridecia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b096eff0-2b5c-4eaa-927c-22775e83ea00
GET /v1/drugs/b096eff0-2b5c-4eaa-927c-22775e83ea00?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Adempas 2 mg",
  "name_fr": "Adempas 2 mg",
  "name_nl": "Adempas 2 mg",
  "amp_code": "SAM458231-00",
  "strengths": [
    "2.0000",
    "2.0000",
    "35.8000"
  ],
  "pack_count": 5,
  "substances": [
    "Riociguat",
    "Lactose Monohydrate",
    "Propylene Glycol",
    "Sodium Laurilsulfate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Riociguat",
  "authorisation_numbers": [
    "EU/1/13/907/011",
    "EU/1/13/907/010",
    "EU/1/13/907/012",
    "EU/1/13/907/019"
  ]
}
API referenceMCP serverPlans

See everything about riociguat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console